CBER staff changes
This article was originally published in The Gray Sheet
Executive Summary
Sixty-three of 213 CBER Office of Therapeutic Research & Review FTEs are reassigned to CBER's Office of Cellular Tissue & Gene Therapies, while the remaining FTEs will be transferred to the drug center, FDA reports. The Jan. 8 agency memo details phase two of a three-part plan to shift review of biologic therapeutic products to the Center for Drug Evaluation & Research. The restructuring was announced last fall (1"The Gray Sheet" Nov. 22, 2002, p.11)...